William Blair analyst Matt Phipps has maintained their bullish stance on AUTL stock, giving a Buy rating today.
Matt Phipps has given his Buy rating due to a combination of factors surrounding Autolus Therapeutics’ recent developments. The company’s successful launch of Aucatzyl, a treatment for adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia, has been a significant milestone. With the FDA approval received in November, Autolus has been proactive in setting up treatment centers, surpassing their initial target by authorizing 33 centers, which covers a substantial portion of the target population in the U.S.
Additionally, the anticipation of the first Phase I data for obe-cel in autoimmune disease from the CARLYSLE study, set to be presented in April, adds to the positive outlook. The inclusion of Aucatzyl in the NCCN treatment guidelines for R/R B-ALL further strengthens its market position. These strategic advancements and the potential for future growth underpin Phipps’s optimistic Buy rating for Autolus Therapeutics.
In another report released today, Needham also maintained a Buy rating on the stock with a $10.00 price target.